Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sands, J. M.
Right arrow Articles by Mitch, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sands, J. M.
Right arrow Articles by Mitch, W. E.

Journal of the American Society of Nephrology, Vol 1, Issue 9 1081-1086, Copyright © 1991 by American Society of Nephrology

REGULAR ARTICLES

Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation

JM Sands, JF Neylan, RA Olson, DP O'Brien, JD Whelchel and WE Mitch
Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322.

Atrial natriuretic factor (ANF) ameliorates renal damage in animal models of acute ischemic renal failure. Consequently, ANF could blunt acute tubular necrosis related to ischemia that occurs frequently in cadaveric renal transplants. Ten pairs of cadaveric kidneys were transplanted into 20 recipients. Paired recipients received either alpha-human ANF (hANF) or vehicle alone in a prospective, double-blind protocol. Upon revascularization of the allograft, either hANF or vehicle was administered intravenously as a 50-micrograms bolus, followed by a 4-h infusion (0.1 microgram/kg/min). Glomerular filtration rate ([125I]iothalamate clearance) was measured between 4 and 7 days posttransplant and again between 14 and 21 days posttransplant. Serum creatinine was measured daily when patients were in the hospital, then twice weekly as patients were examined in the outpatient clinic. Between the groups, there was no significant difference in age of the recipients or donors, cold ischemia time, or histocompatibility leukocyte antigen match. Infusion of hANF had no adverse effects. When subjects receiving hANF were compared with those treated with vehicle alone, there were no significant differences in serum creatinine or glomerular filtration rate. Three hANF and four vehicle recipients required dialysis postoperatively. At 1 month posttransplant, 19 of 20 patients had functioning allografts; an allograft from one hANF recipient never functioned. It was concluded that hANF, when given by the protocol of this study, had no beneficial effect on the outcome of cadaveric renal transplantation in humans.


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
J. W. Sear
Kidney dysfunction in the postoperative period
Br. J. Anaesth., July 1, 2005; 95(1): 20 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
D. L. Vesely
Natriuretic peptides and acute renal failure
Am J Physiol Renal Physiol, August 1, 2003; 285(2): F167 - F177.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. L Vesely
Atrial natriuretic peptides in pathophysiological diseases
Cardiovasc Res, September 1, 2001; 51(4): 647 - 658.
[Full Text] [PDF]

Home page
 NEJMHome page
R. Thadhani, M. Pascual, and J. V. Bonventre
Acute Renal Failure
N. Engl. J. Med., May 30, 1996; 334(22): 1448 - 1460.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673